Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PolynovoCALZF 74 EV-to-EBIT is 150.93 as of Jul. 29, 2026. GuruFocus rates CALZF with a GF Score™ of 74/100 and a GF Value™ of $2.17 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Polynovo ranks worse than 95.94% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Polynovo's Enterprise Value for the quarter that ended in Dec. 2025 was $531.57 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Polynovo's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $2.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polynovo EV-to-EBIT Related Terms
Polynovo EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Polynovo's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Polynovo's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Polynovo's EV-to-EBIT falls into.
Polynovo's current Enterprise Value is $402.53 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Polynovo's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $2.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polynovo (CALZF) has a EV-to-EBIT of 150.93 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Polynovo and its competitors. According to the industry distribution chart, Polynovo ranks #449 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 95.9%.
Is Polynovo's EV-to-EBIT too high?
Polynovo's current EV-to-EBIT is 150.93. The Medical Devices & Instruments industry median EV-to-EBIT is 18.70. Polynovo's value of 150.93 is 707.3% above this industry median. Based on the distribution chart, Polynovo ranks #449 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Polynovo has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #449 out of 468 companies for EV-to-EBIT. This places Polynovo in the lower half of its industry. The industry median EV-to-EBIT is 18.70. Polynovo's value of 150.93 is 707.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.70, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polynovo's current EV-to-EBIT of 150.93 is 707.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Polynovo and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current EV-to-EBIT is 150.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $0.56 — trading 74.2% below its estimated fair value. The current EV-to-EBIT is 150.93 and 707.3% above the Medical Devices & Instruments industry median of 18.70. Polynovo's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Polynovo (CALZF), the current EV-to-EBIT is 150.93 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (CALZF) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of $0.56 is trading 74.2% below its estimated GF Value™ of $2.17.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for CALZF:
EV-to-EBIT: 150.93
GF Value™: $2.17 vs. price of $0.56 (74.2% below fair value)
Industry Position: 707.3% above the Medical Devices & Instruments median (#449 of 468)
No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
74GF Score
Get the complete analysis for CALZF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CALZF has been successfully added to your 
